You are here

  • Home
  • Archive
  • Volume 16, Issue 3
  • Pemetrexed (Alimta®, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial

Article metrics

Article menu
Download PDFPDF
ORIGINAL ARTICLE
Pemetrexed (Alimta®, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial

 

Online download statistics by month:

Online download statistics by month: March 2019 to May 2023

AbstractFullPdf
Mar 20191600
Apr 20191600
May 20191701
Jun 2019800
Jul 20191801
Aug 2019800
Sep 2019500
Oct 2019700
Nov 20191200
Dec 2019801
Jan 20201802
Feb 20202200
Mar 2020200
Apr 2020400
May 20201100
Jun 20201001
Jul 20202902
Aug 2020600
Sep 20201400
Oct 20205500
Nov 20203400
Dec 20201200
Jan 20212402
Feb 2021400
Mar 2021600
Apr 2021600
May 2021201
Jun 2021300
Jul 2021101
Aug 2021202
Sep 2021205
Oct 20211201
Nov 2021508
Dec 20211402
Jan 20221600
Feb 20222201
Mar 20222501
Apr 20221700
May 20224001
Jun 20223904
Jul 20221501
Aug 20222902
Sep 20222600
Oct 20223601
Nov 20221000
Dec 20222600
Jan 20232202
Feb 20235800
Mar 2023800
Apr 20231004
May 20232102
Total833049